Strand Therapeutics reports promising start for mRNA cancer therapy

Ayisha Sharma

News Reporter

A Boston biotech with self-replicating mRNA technology has shared early data from its lead candidate for cancers that are refractory to immune checkpoint inhibitors. …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

Strand Therapeutics reports promising start for mRNA cancer therapy

Ayisha Sharma

News Reporter

Sign up to read this article for free.

FDA rejects Stealth's rare disease drug, but offers potential for accelerated approval

Merck, Daiichi Sankyo scrap FDA application for HER3 ADC after survival miss

DNA giant Illumina spawned an ecosystem of competitors and customers

Updated: Trump administration halts more than $750M in funds for Moderna’s bird flu vaccine

Intellia reports case of liver toxicity in ATTR gene editing study

From weeks to days: how Aizon Intelligent Agents transform pharma validation

Strand Ther­a­peu­tics re­ports promis­ing start for mR­NA can­cer ther­a­py

Ayisha Sharma

News Reporter

Sign up to read this article for free.

FDA re­jects Stealth's rare dis­ease drug, but of­fers po­ten­tial for ac­cel­er­at­ed ap­proval

Mer­ck, Dai­ichi Sankyo scrap FDA ap­pli­ca­tion for HER3 ADC af­ter sur­vival miss

DNA gi­ant Il­lu­mi­na spawned an ecosys­tem of com­peti­tors and cus­tomers

Up­dat­ed: Trump ad­min­is­tra­tion halts more than $750M in funds for Mod­er­na’s bird flu vac­cine

In­tel­lia re­ports case of liv­er tox­i­c­i­ty in AT­TR gene edit­ing study

From weeks to days: how Aizon In­tel­li­gent Agents trans­form phar­ma val­i­da­tion

Strand Therapeutics reports promising start for mRNA cancer therapy

FDA rejects Stealth's rare disease drug, but offers potential for accelerated approval

Merck, Daiichi Sankyo scrap FDA application for HER3 ADC after survival miss

DNA giant Illumina spawned an ecosystem of competitors and customers

Updated: Trump administration halts more than $750M in funds for Moderna’s bird flu vaccine

Intellia reports case of liver toxicity in ATTR gene editing study

From weeks to days: how Aizon Intelligent Agents transform pharma validation